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Abstract
Background: Visceral leishmaniasis is a systemic parasitic disease that is fatal unless treated. We assessed the cost and cost-
effectiveness of alternative strategies for the treatment of visceral leishmaniasis in the Indian subcontinent. In particular we
examined whether combination therapies are a cost-effective alternative compared to monotherapies.
Methods and Findings: We assessed the cost-effectiveness of all possible mono- and combination therapies for the
treatment of visceral leishmaniasis in the Indian subcontinent (India, Nepal and Bangladesh) from a societal perspective
using a decision analytical model based on a decision tree. Primary data collected in each country was combined with data
from the literature and an expert poll (Delphi method). The cost per patient treated and average and incremental cost-
effectiveness ratios expressed as cost per death averted were calculated. Extensive sensitivity analysis was done to evaluate
the robustness of our estimations and conclusions. With a cost of US$92 per death averted, the combination miltefosine-
paromomycin was the most cost-effective treatment strategy. The next best alternative was a combination of liposomal
amphotericin B with paromomycin with an incremental cost-effectiveness of $652 per death averted. All other strategies
were dominated with the exception of a single dose of 10mg per kg of liposomal amphotericin B. While strategies based on
liposomal amphotericin B (AmBisome) were found to be the most effective, its current drug cost of US$20 per vial resulted
in a higher average cost-effectiveness. Sensitivity analysis showed the conclusion to be robust to variations in the input
parameters over their plausible range.
Conclusions: Combination treatments are a cost-effective alternative to current monotherapy for VL. Given their expected
impact on the emergence of drug resistance, a switch to combination therapy should be considered once final results from
clinical trials are available.
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Introduction
Despite their toxicity, pentavalent antimonials are still widely
used as first line treatment for visceral leishmaniasis (VL) except in
the Indian subcontinent where emerging drug resistance in Bihar
State in India [1] and Nepal [2] required a change in drug policy.
Current therapeutic options include amphotericin B deoxycholate
(AmB), liposomal amphotericin B (L-AmB), miltefosine (MF) and
paromomycin (PM). The VL elimination initiative launched in 2005
by the governments of India, Nepal and Bangladesh adopted
miltefosine as the first line treatment [3,4]. More recently
paromomycin was registered in India as a first line regimen for
VL [5]. However, parasite resistance to MF and PM can be induced
experimentally [6] and is expected to emerge naturally if optimal
adherence cannot be ensured [7]. The World Health Organization
has recommended the use of liposomal amphotericin B (L-AmB)
based on high efficacy and safety [8].While the development of
resistance has not yet been demonstrated for AmB and L-AmB,
practicalities (requirements for cold chain and intravenous perfu-
sion) and the high drug cost have so far delayed its adoption as first
line treatment. As there are no new compounds for VL expected to
come to the market in the near future, policies that delay or prevent
the emergence of resistance to the currently available drugs are
therefore required. A possible strategy that has been successfully
used for malaria and tuberculosis is the use of combination therapies
[9]. Combination therapies may also increase tolerability, reduce
treatment duration and possibly (direct and indirect) costs.
Phase III clinical trials of combination therapies for VL are
currently underway testing the efficacy and safety of several
combinations and results are expected in 2010 (Clinicaltrial.gov,
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Identifier: NCT00696969; for more information see http://
clinicaltrials.gov/). Choices in VL drug policy should be based
on efficacy, safety as well as the cost of treatment, the process of
patient management and the factors influencing treatment
effectiveness, such as adherence. The latter factor is particularly
important as some regimens (e.g.injectables) are likely to lead to
higher compliance than others.
The objective of the present study was to assess the cost-
effectiveness of various treatment options for VL, and in particular
to evaluate whether combination therapies are a cost-effective
alternative to monotherapy.
Methods
Description of alternatives
We considered 10 alternative treatment strategies: (1) all
monotherapies that are either already implemented or under
consideration and (2) combination therapies currently included in
a phase III clinical trial (See table 1). AmB has infusion-related and
delayed toxicities (e.g.nephrotoxicity) [10] and requires prolonged
parenteral administration and hospitalisation. MF has the
advantages of an oral drug but causes serious adverse events in
2–3% of patients [11] , has a long half-life and is possibly
teratogenic. It can thus not be used in pregnant women and
women in child-bearing age should accept contraception over the
treatment period and up to two months after [12]. PM seems a
safer option - though phase IV results are still pending - and
relatively cheap, but requires intramuscular injections. L-AmB is
highly efficacious (.90%) even in a single dose of 5–10 mg/kg in
India [13–15] and is safe, but it is expensive despite a preferential
price offered by the manufacturer to the public sector and requires
an efficient cold chain. All of the other more ‘‘affordable’’
monotherapies listed above (MF, PM, AmB) require prolonged
treatment which is problematic in very poor population groups
that are dependent on daily labour and pay much out-of-pocket.
Decision model
A decision tree model, depicted in figure 1, was developed using
TreeAge Pro Suite v2009 (TreeAge Software Inc., Williamstown,
MA, USA) to determine the outcome of a single confirmed VL
patient receiving first-line treatment at a primary health care
facility. The outcome was expressed in terms of number of deaths
averted and we assumed a case-fatality rate of 100% in the
absence of treatment. For each treatment strategy, the patient
either adheres or does not. Those adhering are either cured or
experience treatment failure. Patients not adhering to treatment
were considered lost to follow-up and we assigned a value of 0
deaths averted. For strategies combining L-AmB with MF or PM,
we assigned a value of 0.91 in case of non-adherence since patients
will have received a single dose of 5mg/kg of L-AmB (with 91%
cure rate) [16,17] on the first day before they are lost to follow-up.
Since MF is contraindicated in pregnant and breastfeeding women
or women in child bearing age because of its potential teratogenic
effect, the path for strategies including MF is different from those
without MF. MF can only be given if the patient accepts the use of
contraceptive measures during treatment and up to two months
after completion of treatment. This is captured in the model by
including an additional probability representing the contraceptive
prevalence in the community. We calculated the cost per case
treated and the average and incremental cost-effectiveness ratios
(ICERs) expressed as the cost per death averted. The ICER
represents the additional cost to gain an additional unit of
effectiveness (i.e. one additional death averted) and is calculated by
dividing the incremental cost of a given strategy by its incremental
effectiveness compared to the previous not dominated strategy.
Furthermore we assumed in the baseline analysis the patient to be
hospitalized for at least one day for all strategies; for treatment with
AmB the patient is hospitalized for the entire duration of treatment
(30 days) as this drug needs to be given under close supervision.
Strategies with PM and SSG are provided on an outpatient basis
whereby the patient visits the health facility daily to receive the
intramuscular injection. In the case of treatment with MF, the patient
visits the health facility weekly to receive a 1-week supply of the drug.
We also assumed patients to undergo weekly routine laboratory
investigations (blood count, liver and renal function tests), a
pregnancy test for women in child-bearing age and an HIV test.
Author Summary
Visceral leishmaniasis (VL) is a serious health problem in
the Indian subcontinent affecting the rural poor. It has a
significant economic impact on concerned households.
The development of drug resistance is a major problem
and threatens control efforts under the VL elimination
initiative. With an unprecedented choice of antileishmanial
drugs (but no newer compound in clinical development),
policies that protect these drugs against the emergence of
resistance are required. A possible strategy that has been
successfully used for malaria and tuberculosis is the use of
combination therapies. This study is the first comprehen-
sive assessment of the cost-effectiveness of all possible
mono- and combination therapies for the treatment of
visceral leishmaniasis in the Indian subcontinent. The
analysis was done from the societal perspective, including
both health provider and household costs. The present
work shows that combination treatments are a cost-
effective alternative to current monotherapy for VL. Given
their expected impact on emergence of drug resistance,
the use of combination therapy should be considered in
the context of the VL elimination programme in the Indian
subcontinent.
Table 1. Overview of treatment strategies included in
decision analysis model.
Strategy Drug
Length of
treatment
(days)
A L-AmB (5MK)+Miltefosine (50/100 MD) 8
B L-AmB (5MK)+Paromomycin sulphate (15 MKD) 11
C Miltefosine (50/100 MD)+Paromomycin sulphate
(15 MKD)
10
D SSG (20 MKD)+Paromomycin sulphate (15 MKD) 17
E Miltefosine (50/100 MD) 28
F Paromomycin sulphate (15 MKD) 21
G Amphotericine B deoxycholate (1 MK eod) 30
H L-AmB10 (10 MK) 1
I L-AmB20 (5 MKD) 4
J Sodium Stibogluconate (20 MKD) 30
- L-AmB : Liposomal Amphotericine B.
- MK=mg/kg single dose; MD=mg per day; MKD=mg/kg body weight per
day.
- Miltefosine is given at 50 mg/day if body weight is ,25 or 100 mg if body
weight $25 kg per day.
doi:10.1371/journal.pntd.0000818.t001
Cost-Effectiveness of Kala-Azar Treatment
www.plosntds.org 2 September 2010 | Volume 4 | Issue 9 | e818
Probabilities
The probabilities used in the model are shown in table 2. These
consist of a most plausible value used in the baseline analysis and the
range used in the sensitivity analysis. We used anthropometric data
from a sample of 1496 patients attending a dedicated VL treatment
centre in Muzaffarpur, Bihar (India) [18] to derive probabilities on
patient characteristics (age, weight and sex). Other values were
obtained from expert opinion and published literature. To derive
the probabilities related to efficacy and compliance for therapies
that are still in clinical trials, we consulted a group of VL experts in
an adapted Delphi process to reach consensus after two consultation
rounds. In the first round seven clinical experts were presented with
a survey asking for efficacy and compliance values for all treatments.
Subsequently results from this round were summarized and
presented to the experts to revise their earlier answers (round 2).
For estimates derived from the literature, we used data from clinical
trials using the pooled estimate in the baseline analysis and used the
minimum and maximum for sensitivity analysis. All estimates
represent definite cure rates defined as the absence of VL at 6
month follow-up; failure, relapse and fatal toxicity are included in
the estimates. While minor side effects, such as diarrhoea and
vomiting may occur, we did not consider these in the model since
they do not hamper the completion of treatment.
We assumed treatments of short duration (strategies A, B, C, H
and I) to result in high compliance. Similarly, treatment with AmB
was assumed to lead to high compliance since treatment is provided
on an inpatient basis. On the other hand, patients receiving MF for
28 days receive a 1-week supply of drug at a time for self-
administration and compliance is anticipated to be lower than for the
other strategies, consistent with findings from a miltefosine phase IV
study by Bhattacharya et al (2007) [11] where the final cure rate was
82% on intent-to-treat analysis due to the high losses to follow-up.
Costs
Table 3 summarizes cost estimates presented in 2008 US dollars
(US$). Costs were obtained from primary data collected in 2008
using an ingredients based approach (i.e. collecting information on
quantities and prices) and supplemented by data from the literature.
We adopted a societal perspective including both provider and
patient costs. These costs consist of direct medical costs (e.g.
antileishmanial drugs, administration kits (intravenous sets, syringes
and needles), laboratory investigations and the cost of hospitaliza-
tion and outpatient care); direct non-medical costs (transportation
to/from the health facility) and indirect costs representing the loss of
income to the patient. The cost of drugs was obtained from WHO,
Me´decins sans Frontie`res (MSF) and the Institute of One World
Health (iOWH). The cost of L-AmB was US$ 20 per 50 mg vial
(AmBisome, Gilead, USA), MF (Impavido previously Zentaris,
Germany, now Paladin, Canada) US$ 1.41 per 100 mg capsule (or
US$ 79 per blister of 56 capsules; the market price of US$ 2.68 per
capsule was used as the maximum value in the range), PMUS$ 0.71
per 1000 mg ampoule (Gland Pharma Ltd, India), AmB US$ 1.90
per mg vial (Combinopharm, Spain) and SSG US$ 8.25 per vial
(Albert David, India). The average drug cost per patient for each
strategy was estimated using the anthropometric database. The
baseline cost of laboratory investigations includes the cost of
equipment, supplies, reagents, the technician’s time and indirect
laboratory costs (i.e. overhead costs obtained through step-down
costing) and is an average cost calculated at a VL treatment centre
in India (Muzaffarpur) and a health facility in Nepal (Dharan). The
range consists of prices charged to patients at public health facilities
and private laboratories. The unit cost per inpatient bed-day and
outpatient visit was estimated at a charitable clinic in India [19].
The maximum value used in the range was derived from WHO-
CHOICE estimates for the South Asian region [20]. Average
income was estimated with the human capital approach and was
estimated at US$ 1.48 per day [19]. We assumed that the patient
was not able to work for the full duration of treatment. Indirect costs
were varied from 0 (i.e. excluding indirect costs) to twice the baseline
value in sensitivity analysis. Costs related to diagnosis of VL
were not included in the analysis since these are the same for all
strategies.
Figure 1. Root decision tree with different pathways depending on whether miltefosine is included in the strategy.
doi:10.1371/journal.pntd.0000818.g001
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All costs were adjusted to the 2008 national currency of each
country using the consumer price index and converted to US
dollars using the exchange-rate prevailing at that time.
Sensitivity analysis
To examine the uncertainty around variables and how these
affect the outcome and conclusions of our study, we conducted a
series of one-way and two-way sensitivity analyses. Since values for
drug efficacy and compliance were largely based on expert opinion
we varied the values of these variables over the plausible range
specified in table 2. On the cost side, we examined the impact of
changing drug prices. While the price of most drugs, such as PM or
AmB is unlikely to change much in the future given their low cost,
there is uncertainty with regard to the pricing of MF and L-AmB.
MF was recently acquired by Paladin Labs Inc., Canada from
Zentaris, and it is at the time of writing unclear if the current
negotiated differential prices will be maintained. For L-AmB,
despite substantial price reductions, the cost per vial remains high
and there may be room for further price reductions. To test the
robustness of our results we (i) varied each drug cost separately; (ii)
conducted a threshold analysis to determine at what price level
strategies with L-AmB become the most cost-effective; and (iii)
conducted a two-way sensitivity analysis of the price of MF and L-
AmB. We also varied the unit cost per inpatient bed-day and
outpatient visit. Finally, we examined the impact of indirect costs. In
the baseline analysis we assumed the patient would not be able to
work for the full duration of treatment. But in practice, with effective
treatment, patients may already feel better after a week of treatment
and resume their activities. The indirect cost of strategies with
longer treatment duration could therefore be overestimated. In
addition the inclusion of indirect costs is a controversial issue,
mainly due to the valuationmethod [21].We therefore looked at the
impact of indirect costs by (i) limiting productivity losses to a week,
and (ii) excluding indirect costs from estimations.
Results
Baseline analysis
Table 4 shows the expected cost and effectiveness for each
treatment strategy using baseline values. Strategies were ranked in
Table 2. Model parameters.
Variable Likeliest (base) Minimum Maximum Source
Demographic parameters of sample (%)b
Women in the sample 39 30 50 [18,34]
Women of childbearing age (15–49 yrs) of all VL 17 10 35 [18,34]
Patients weighing less than 25 kg 41 20 60 [18,34]
Children (0–14 years) 51 25 75 [18,34]
Adults (15–80 years) 49 25 75 [18,34]
Drug efficacy (%)
L-AmB + MF 95 90 99 a; [16]
L-AmB + PM 95 90 99 a
MF + PM 95 91 99 a
SSG + PM 90 85 98 a; [34,35]
MF 94 82 94 [12,34,36–38]
PM 94 89 95 a; [5,39–41]
AmB 97 96 99 [5,10,12,42]
L-AmB10 95 93 98 a; [15]
L-AmB20 95 93 99 a; [43]
SSG 70 35 93 [1,2,34,39,41,44–47]
Compliance to treatment (%)
L-AmB + MF 95 80 97 a
L-AmB + PM 95 85 97 a
MF + PM 95 80 97 a
SSG + PM 83 75 90 a
MF 80 60 90 a; [11]
PM 85 75 90 a
AmB 90 80 90 a
L-AmB10 100 - - a
L-AmB20 98 95 100 a
SSG 75 60 90 a
Contraceptive prevalence (%) 55 30 70 a; WHO-WHOSISc
aEstimates obtained from expert opinion (Delphi method).
bBaseline values were varied 650% in sensitivity analysis.
cAverage of figures reported for Bangladesh 58.1% (2004); India 56.3% (2006); Nepal 48.0% (2006).
doi:10.1371/journal.pntd.0000818.t002
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ascending order of costs. Strategies based on treatment with L-
AmB, either used as a single agent or in combination, were found
to be more effective compared to other strategies with a single dose
of 10mg/kg of L-AmB (strategy H) being the most effective and
averting 95% of deaths. This high effectiveness of strategies with
L-AmB is explained by the combination of high drug efficacy and
a short treatment duration resulting in high expected compliance
to treatment. After strategies with L-AmB, the next best alternative
is the co-administration of MF and PM (strategy C) averting 90%
of deaths. Monotherapies with either SSG (strategy J) or MF
(strategy E) had the lowest effectiveness. For SSG this is due to the
low efficacy of the drug and for MF due to the low expected
treatment compliance.
The least costly treatment is the co-administration of MF with
PM (strategy C) with a cost of $72.9 per patient treated. The cost
per patient treated for the other strategies varied from $96.6
(strategy F) to $311.6 (strategy I). The breakdown of costs for each
strategy is shown in table 3. The drug cost as a proportion of total
costs is the highest for strategies including L-AmB. The price of a
50mg vial of L-AmB at the time of this analysis was $ 20 and is the
most expensive VL drug. Obviously, the higher the dosage, the
more expensive the treatment. For example the drug cost of
strategy I (20mg/kg of L-AmB for 4 days) is $280. The highest
‘‘other’’ direct medical costs were found for strategies requiring
prolonged treatment, with treatment on an inpatient basis (strategy
G) being the most expensive. Similarly, strategies with long
treatment duration and/or requiring many visits to the health
facility for administration of the drug have the highest indirect
cost.
Cost-effectiveness results are illustrated in figure 2 and reported
in table 4. All treatment strategies on the left of the line are
dominated by strategies C, B and H because they are equally or
less effective, and either cost more (strong dominance) or have an
incremental cost-effectiveness ratio that is higher than the next
more effective strategy (extended dominance). The incremental
cost, incremental effectiveness, cost-effectiveness ratio (CER) and
incremental CER without the dominated strategies are reported in
table 5.
The most cost-effective strategy appears to be strategy C
whereby MF and PM are co-administered. Compared with this
strategy, the next most cost-effective strategy is the combination of
L-AmB with PM (strategy B), followed by a single dose of 10mg/kg
Table 3. Cost estimates of each treatment strategy per patient treated (US$ 2008).
Strategy Drug cost Other direct medical1 Non-medical & indirect Total cost2
L-AmB+MF 95.7 14.8 12.8 123.4
L-AmB+PM 87.1 20.5 25.3 132.9
MF+PM 29.5 19.5 23.8 72.9
SSG+PM 45.1 29.9 43.6 118.6
MF 62.8 22.0 45.4 130.2
PM 14.9 30.6 51.1 96.6
AmB 20.9 131.6 45.4 197.9
L-AmB10 140.0 11.0 2.5 153.4
L-AmB20 280.0 24.7 6.9 311.6
SSG 57.8 40.7 73.4 171.8
1Includes costs of contraceptives, administration (intravenous kits, solutions, syringes), laboratory investigations. It also includes the cost per inpatient bed-day and
outpatient visit obtained.
2Total costs of strategies with MF in this table do not include cost of AmB given to women in childbearing age that refuse to take contraceptives and are therefore
different from total costs mentioned in table 4.
doi:10.1371/journal.pntd.0000818.t003
Table 4. Results in the baseline analysis.
Strategy Cost (C) Incremental Cost* Effectiveness (E) Incremental Effectiveness* C/E Incremental C/E (ICER)**
MF + PM 82.5 0.900 92
PM 96.6 14.1 0.799 20.101 121 (Dominated)
SSG + PM 118.6 36.1 0.747 20.153 159 (Dominated)
L-AmB + MF 129.1 46.6 0.942 0.042 137 1123**
L-AmB + PM 132.9 3.8 0.948 0.006 140 652
MF 135.4 2.5 0.761 20.186 178 (Dominated)
L-AmB 10 153.4 20.6 0.950 0.002 162 8224
SSG 171.8 18.4 0.525 20.425 327 (Dominated)
AmB 197.9 44.5 0.873 20.077 227 (Dominated)
L-AmB 20 311.6 158.2 0.949 20.001 328 (Dominated)
*Numbers in the table are rounded.
**Extended dominance.
doi:10.1371/journal.pntd.0000818.t004
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of L-AmB (strategy H). While L-AmB combined with MF (strategy
A) is more effective than strategy C, it is also more costly and has a
higher (incremental) cost-effectiveness ratio that the next best
alternative (i.e. strategy B). In other words the additional cost per
death averted is lower for strategy B than strategy A.
Sensitivity analysis
The study findings were robust to most changes in the input
variables. Varying the values of the drug efficacy and compliance
over their plausible range did not affect the ranking of strategies. A
sensitivity analysis assuming that all non-adherent patients would
effectively be cured did not change the ranking of strategies either.
With regard to costs, while varying the price of MF did not alter
results, the cost-effectiveness results were sensitive to a change in
the price of L-AmB. If the price of a vial is decreased by more than
51% to less than $ 9.8, then strategy H becomes the most cost-
effective strategy. The relationship between the price of MF and
the price of L-AmB and their impact on the ranking of strategies
according to their cost-effectiveness, keeping all other variables at
their baseline values is shown in figure 3. If MF is purchased at
market price ($ 2.68 per capsule), the price per vial of L-AmB would
need to decrease to below $12.5 for strategy H to become the most
cost-effective strategy. Varying the assumptions regarding indirect
cost did not change conclusions.
Discussion
The current first line regimen in the Indian subcontinent is MF
for 28 days. There are concerns however that the uncontrolled
provision of the drug may increase the likelihood of development
of parasite resistance [22]. Even when monitored, patient
compliance is not optimal [11,22] and the risk remains that
women in childbearing age receiving MF do not (or only partially)
take contraceptives. Our analysis shows that combination
Figure 2. Cost-effectiveness ratio (US$/death averted) of 10 treatment strategies for visceral leishmaniasis. Line CBH shows
dominance. All strategies left of this line are dominated by C, B and H, meaning they are equally or less effective and more costly.
doi:10.1371/journal.pntd.0000818.g002
Table 5. Baseline results without dominated options (simple or extended).
Strategy Cost Incremental Cost Effect Incremental Effect C/E Incremental C/E (ICER)
MF + PM 81.9 0.900 91
L-AmB + PM 132.9 51.0 0.948 0.047 140 1079
L-AmB10 153.4 20.6 0.950 0.002 162 8224
doi:10.1371/journal.pntd.0000818.t005
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therapies for the treatment of VL are a cost-effective alternative to
the current strategy in the Indian subcontinent; this finding may
be of interest to control programmes regarding the cost-
effectiveness of the currently recommended option. The co-
administration of MF with PM for 10 days seems to be the most
cost-effective option because of the combined effect of low cost,
especially drug cost, and high effectiveness. Also, one would expect
that the parenteral intramuscular injection of PM by health
workers ensures that patients also take the oral MF as it would be
directly observed. With the short treatment duration this is likely
to result in high patient compliance, increasing the overall
effectiveness of the strategy. Although strategies with L-AmB were
the most effective, the high drug cost results in a higher average
cost-effectiveness. The next best alternative compared to the
combination MF/PM was a combination of L-AmB with PM with
an incremental cost-effectiveness of $652 per death averted. All
other strategies, with the exception of a single dose of 10mg per kg
of liposomal amphotericine B were dominated. The relatively poor
effectiveness for MF monotherapy in our model is linked to the
estimated low adherence when using self-administration with 1-
weekly drug supplies. However, alternative drug delivery strategies
for MF monotherapy are possible. A strategy where intake of MF
would be directly observed would result in significantly higher
effectiveness, although at higher direct and indirect costs. When
we ran a sensitivity analysis with MF compliance put at 100%, this
did not change the ranking of strategies or conclusions.
This study is the most comprehensive cost-effectiveness analysis
of alternative strategies for the treatment of VL for the Indian
subcontinent to date. We used a simple decision analytical model
to compare from a societal perspective the cost and outcome of all
possible treatment strategies identified through consultation with
experts (Delphi method). The demographic probabilities used in
the model, as well as the calculation of the average drug cost was
based on real patient data on sex, age and weight obtained from a
charitable medical facility in India [23], instead of calculating the
drug cost of an ‘‘average’’ 35kg patient as done in other studies. In
addition, all cost data in the baseline analysis were based on
primary data collected from various sites in Nepal and India.
Extensive sensitivity analysis was also done to evaluate the
robustness of our estimations and conclusions. The analysis has
several limitations. First while the use of the anthropometric data
can be a strength, the VL treatment centre in Muzaffarpur (Bihar)
might not be entirely representative for all VL cases, especially
with regard to the male to female ratio. Reassuringly, in a larger
series of 4170 patients from two locations in Bihar and 1311 from
Nepal the male to female ratio was similar (57:43, Olliaro et al,
manuscript submitted). Although various studies have reported a
higher proportion of male patients to be affected by kala-azar
[24,25] there may be under-reporting of kala-azar in women [26]
due to sex-selective treatment seeking whereby ‘‘fewer women may
seek treatment because of its expense’’ [27]. A M/F ratio in the
VL population closer to unity could lower the effectiveness of
strategies including MF. Second, the drug efficacy estimates for the
combination treatments, and the monotherapies with L-AmB were
based on input from a Delphi survey of VL experts. The
uncertainty surrounding these subjective estimates was minimized
by including experts that were clinicians and/or involved in
clinical trials of combination treatments and dose-finding studies.
Figure 3. Two-way sensitivity analysis on price of AmBisome and miltefosine.
doi:10.1371/journal.pntd.0000818.g003
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The uncertainty was also analysed extensively in sensitivity
analysis. Third the effectiveness estimates are heavily influenced
by the parameters of patient compliance to treatment. Experts
assumed treatments with parenteral or intramuscular administra-
tion to lead to high compliance and oral treatment to result in
lower patient compliance. Given the evidence from the interna-
tional literature for other diseases, and the limited information
available for kala-azar [11,28], these assumptions seem plausible.
As more evidence becomes available from clinical trials (especially
Phase IV and other operational studies) and future studies
assessing patient compliance, we will update the input parameters
and ranges from our model. Finally, some cost variables were not
included in the analysis. L-AmB requires a cold chain. Because it
was difficult to quantify the cost of the cold chain, we did not
include it in our calculations and the cost per patient treated and
cost per death averted may therefore be an underestimation.
There is, moreover, also a substantial risk of breakdowns in the
cold chain system, which may impact on the efficacy of the drug.
Governments may want to adapt the drug policy choice to the
technology constraints in each level of the health system.
Few other studies have investigated the cost-effectiveness of VL
treatment strategies. Vanlerberghe et al (2007) [29] compared
various monotherapies from a health service perspective (not
including paromomycin) and found a strategy with miltefosine to
be the most cost-effective with US$328 per death averted.
Although the study uses a similar decision tree model and
sensitivity analysis to account for uncertainty in the input
parameters, the results from this study cannot be compared with
ours. The model by Vanlerberghe et al. starts with a clinical
suspect going through diagnosis and then treatment. Treatment
effectiveness is therefore defined by probabilities other than those
directly related to treatment such as the prior probability of
disease, and the sensitivity and specificity of the diagnostic test.
Patient compliance was not modelled either. A more recent study
by Olliaro et al. (2009) [30] compared various monotherapies and
a combination of L-AmB with MF with different total dosages for
MF from a health systems perspective. Similar to our findings,
Olliaro et al show that the combination L-AmB+MF (for 8 days)
with a cost of $124–160 per death averted is more cost-effective
than most monotherapies (the exception being PM delivered in an
outpatient setting and a 5mg/kg single dose formulation of L-
AmB). However this study did not include indirect costs (i.e.
productivity losses) underestimating the effect of strategies with a
short treatment duration that are beneficial to the patient and
household.
Our results highlight that several possible therapeutic options
may exist for the South Asian context - especially in light of the
ongoing VL elimination campaign in the Indian subcontinent -
but combination regimens are efficient options compared to
monotherapy. The analysis should be repeated in other VL-
endemic areas such as East Africa and Brazil where efficacy
outcomes, treatment regimens, direct and indirect costs may differ
considerably. Critical elements of importance to national and
international policy makers are the cost of drugs, the level of out-
of-pocket expenditures by VL patients and compliance to
treatment. An obstacle to the introduction of strategies with L-
AmB in national control programmes is the cost of the drug.
Despite substantial reductions in the price of AmBisome over the
past years (more recently to $18 for a 50mg vial), the threshold
analysis showed this to be not enough to make strategies with L-
AmB a cost-effective alternative. In addition, the capacity of VL
patients and their family to cover the costs of treatment is very
limited. VL is a disease that affects the poorest of the poor [31] and
places a considerable economic burden on households [19,32,33].
Especially in India and Bangladesh, the combination of frequent
drug shortages and poor quality of care in public health facilities
pushes many patients to buy drugs from private pharmacies or to
seek care in the private sector. Unless the government or a
donation programme covers the cost of drugs, strategies including
expensive drugs such as L-AmB will be a barrier to patients and
reduce access to appropriate and effective care resulting in
increased mortality.
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